JP2013529900A - Ｂ細胞活性化因子の拮抗物質、その調製方法及び利用法 - Google Patents
Ｂ細胞活性化因子の拮抗物質、その調製方法及び利用法 Download PDFInfo
- Publication number
- JP2013529900A JP2013529900A JP2013511528A JP2013511528A JP2013529900A JP 2013529900 A JP2013529900 A JP 2013529900A JP 2013511528 A JP2013511528 A JP 2013511528A JP 2013511528 A JP2013511528 A JP 2013511528A JP 2013529900 A JP2013529900 A JP 2013529900A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- amino acid
- antagonist
- seq
- cell activator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003719 b-lymphocyte Anatomy 0.000 title claims abstract description 56
- 239000005557 antagonist Substances 0.000 title claims abstract description 51
- 239000012190 activator Substances 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title claims description 7
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 26
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 26
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 19
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims abstract description 16
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims abstract description 16
- 101100425949 Mus musculus Tnfrsf13c gene Proteins 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 6
- 108700002109 Transmembrane Activator and CAML Interactor Proteins 0.000 claims abstract description 5
- 102000050862 Transmembrane Activator and CAML Interactor Human genes 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 83
- 102000004169 proteins and genes Human genes 0.000 claims description 61
- 239000002773 nucleotide Substances 0.000 claims description 52
- 125000003729 nucleotide group Chemical group 0.000 claims description 52
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 36
- 150000001413 amino acids Chemical class 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 21
- 210000004027 cell Anatomy 0.000 claims description 20
- 239000013604 expression vector Substances 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 15
- 239000013598 vector Substances 0.000 claims description 14
- 239000013612 plasmid Substances 0.000 claims description 13
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 12
- 230000003042 antagnostic effect Effects 0.000 claims description 9
- 201000006754 cone-rod dystrophy Diseases 0.000 claims description 9
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 8
- 238000007792 addition Methods 0.000 claims description 8
- 238000000746 purification Methods 0.000 claims description 8
- 238000012217 deletion Methods 0.000 claims description 7
- 230000037430 deletion Effects 0.000 claims description 7
- 238000006467 substitution reaction Methods 0.000 claims description 7
- 108060003951 Immunoglobulin Proteins 0.000 claims description 6
- 201000000464 cone-rod dystrophy 2 Diseases 0.000 claims description 6
- 239000012228 culture supernatant Substances 0.000 claims description 6
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 238000004440 column chromatography Methods 0.000 claims description 4
- 238000002955 isolation Methods 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- 238000011068 loading method Methods 0.000 claims description 3
- 239000012516 mab select resin Substances 0.000 claims description 3
- 241000702421 Dependoparvovirus Species 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 238000012258 culturing Methods 0.000 claims 1
- 238000010353 genetic engineering Methods 0.000 abstract description 7
- 238000002474 experimental method Methods 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 description 58
- 101710181056 Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 description 56
- 235000018102 proteins Nutrition 0.000 description 40
- 235000001014 amino acid Nutrition 0.000 description 23
- 230000006870 function Effects 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- 229920001184 polypeptide Polymers 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 108010046304 B-Cell Activation Factor Receptor Proteins 0.000 description 5
- 102000007536 B-Cell Activation Factor Receptor Human genes 0.000 description 5
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 5
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
- DYAHQFWOVKZOOW-UHFFFAOYSA-N Sarin Chemical group CC(C)OP(C)(F)=O DYAHQFWOVKZOOW-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 2
- 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 101100244725 Caenorhabditis elegans pef-1 gene Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102100025594 Guided entry of tail-anchored proteins factor CAMLG Human genes 0.000 description 1
- 101000932902 Homo sapiens Guided entry of tail-anchored proteins factor CAMLG Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 150000008575 L-amino acids Chemical group 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241001111421 Pannus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 108091005956 Type II transmembrane proteins Proteins 0.000 description 1
- 108091005966 Type III transmembrane proteins Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000000636 anti-proteolytic effect Effects 0.000 description 1
- 229960003270 belimumab Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940022836 benlysta Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000001280 germinal center Anatomy 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010183905.9 | 2010-05-26 | ||
| CN2010101839059A CN101851278B (zh) | 2010-05-26 | 2010-05-26 | B细胞激活因子拮抗剂及其制备方法与用途 |
| PCT/CN2011/074687 WO2011147320A1 (zh) | 2010-05-26 | 2011-05-26 | B细胞激活因子拮抗剂及其制备方法与用途 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015151930A Division JP6320973B2 (ja) | 2010-05-26 | 2015-07-31 | Ｂ細胞活性化因子の拮抗物質、その調製方法及び利用法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013529900A true JP2013529900A (ja) | 2013-07-25 |
| JP2013529900A5 JP2013529900A5 (enExample) | 2014-12-04 |
Family
ID=42802979
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013511528A Pending JP2013529900A (ja) | 2010-05-26 | 2011-05-26 | Ｂ細胞活性化因子の拮抗物質、その調製方法及び利用法 |
| JP2015151930A Active JP6320973B2 (ja) | 2010-05-26 | 2015-07-31 | Ｂ細胞活性化因子の拮抗物質、その調製方法及び利用法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015151930A Active JP6320973B2 (ja) | 2010-05-26 | 2015-07-31 | Ｂ細胞活性化因子の拮抗物質、その調製方法及び利用法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9290582B2 (enExample) |
| EP (1) | EP2578603B1 (enExample) |
| JP (2) | JP2013529900A (enExample) |
| KR (2) | KR101810551B1 (enExample) |
| CN (1) | CN101851278B (enExample) |
| WO (1) | WO2011147320A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101851278B (zh) * | 2010-05-26 | 2013-03-13 | 石药集团中奇制药技术（石家庄）有限公司 | B细胞激活因子拮抗剂及其制备方法与用途 |
| CN106220740A (zh) * | 2016-08-18 | 2016-12-14 | 中山大学 | 可溶性蛋白baff在b细胞体外培养及扩增的应用 |
| CN115812077A (zh) | 2020-05-08 | 2023-03-17 | 高山免疫科学股份有限公司 | April和baff抑制性免疫调节蛋白及其使用方法 |
| WO2024197157A1 (en) | 2023-03-21 | 2024-09-26 | Biograph 55, Inc. | Cd19/cd38 multispecific antibodies |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010042654A2 (en) * | 2008-10-07 | 2010-04-15 | The Regents Of The University Of California | Recombinant nell protein production |
| CN101851278A (zh) * | 2010-05-26 | 2010-10-06 | 四川大学 | B细胞激活因子拮抗剂及其制备方法与用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA83458C2 (uk) * | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
| DK1436003T3 (da) * | 2001-05-24 | 2010-03-15 | Zymogenetics Inc | TACI-immunoglobulin-fusionsproteiner |
| KR20040019105A (ko) | 2001-08-03 | 2004-03-04 | 제넨테크, 인크. | ＴＡＣＩｓ 및 ＢＲ3 폴리펩티드 및 이의 용도 |
| EP2272868B1 (en) | 2003-06-05 | 2015-03-04 | Genentech, Inc. | Combination therapy for B cell disorders |
| SI1631313T1 (sl) | 2003-06-05 | 2015-06-30 | Genentech, Inc. | Kombinirana terapija za B-celične motnje |
| KR20070107687A (ko) | 2004-12-31 | 2007-11-07 | 제넨테크, 인크. | Ｂｒ３과 결합하는 폴리펩티드, 및 그의 용도 |
| JP2010501622A (ja) | 2006-08-28 | 2010-01-21 | アレス トレーディング ソシエテ アノニム | Ｆｃ−融合タンパク質の精製法 |
| ES2422479T3 (es) * | 2007-03-27 | 2013-09-11 | Zymogenetics Inc | Combinación de inhibición de BLyS y micofenolato de mofetilo para tratamiento de enfermedades autoinmunitarias |
-
2010
- 2010-05-26 CN CN2010101839059A patent/CN101851278B/zh active Active
-
2011
- 2011-05-26 KR KR1020167020322A patent/KR101810551B1/ko active Active
- 2011-05-26 KR KR1020127033484A patent/KR20130043642A/ko not_active Ceased
- 2011-05-26 EP EP11786092.4A patent/EP2578603B1/en active Active
- 2011-05-26 JP JP2013511528A patent/JP2013529900A/ja active Pending
- 2011-05-26 US US13/699,903 patent/US9290582B2/en active Active
- 2011-05-26 WO PCT/CN2011/074687 patent/WO2011147320A1/zh not_active Ceased
-
2015
- 2015-07-31 JP JP2015151930A patent/JP6320973B2/ja active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010042654A2 (en) * | 2008-10-07 | 2010-04-15 | The Regents Of The University Of California | Recombinant nell protein production |
| CN101851278A (zh) * | 2010-05-26 | 2010-10-06 | 四川大学 | B细胞激活因子拮抗剂及其制备方法与用途 |
Non-Patent Citations (3)
| Title |
|---|
| JPN6014029202; Ａｃａｄ Ｊ Ｓｅｃ Ｍｉｌ Ｍｅｄ Ｕｎｉｖ．， ２００６年， 第２７巻， １１９０-１１９５ページ * |
| JPN6014029204; Ｂｉｏｃｈｅｍｉｓｔｒｙ， ２００３年， 第４２巻， ５９７７-５９８３ページ * |
| JPN6014029211; Ｊ Ｂｉｏｌ Ｃｈｅｍ．， ２００５年， 第２８０巻， ７２１８-７２２７ページ * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2578603A1 (en) | 2013-04-10 |
| EP2578603A4 (en) | 2014-03-26 |
| KR20130043642A (ko) | 2013-04-30 |
| KR101810551B1 (ko) | 2017-12-19 |
| KR20160102066A (ko) | 2016-08-26 |
| CN101851278A (zh) | 2010-10-06 |
| JP2016019527A (ja) | 2016-02-04 |
| WO2011147320A1 (zh) | 2011-12-01 |
| US20130089549A1 (en) | 2013-04-11 |
| JP6320973B2 (ja) | 2018-05-09 |
| EP2578603B1 (en) | 2018-11-14 |
| US9290582B2 (en) | 2016-03-22 |
| CN101851278B (zh) | 2013-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5372917B2 (ja) | 最適化されたＴＡＣＩ−Ｆｃ融合タンパク質 | |
| CN106795213B (zh) | 选择性地活化调节性t细胞用于治疗自身免疫病的分子 | |
| KR102685748B1 (ko) | 항암 융합 폴리펩타이드 | |
| US20190106472A1 (en) | Interleukin 15 (IL-15) Antagonists and Uses Thereof for the Treatment of Autoimmune Diseases and Inflammatory Diseases | |
| JP2019001793A (ja) | 免疫グロブリンＦｃ変異体 | |
| DK2633865T3 (en) | USE OF INTERLEUKIN-22 IN THE TREATMENT OF VIRAL HEPATITIS | |
| NZ554481A (en) | Fusion protein that binds to IL-1 receptor and one of IL18, IL4 or IL13 | |
| CN108129574A (zh) | 包括白细胞介素10和白细胞介素4的融合蛋白 | |
| WO2018166468A1 (zh) | IgG样长效免疫融合蛋白及其应用 | |
| JP6320973B2 (ja) | Ｂ細胞活性化因子の拮抗物質、その調製方法及び利用法 | |
| WO2015172305A1 (zh) | 抑制taci-baff复合物形成的融合蛋白及其制法和用途 | |
| CN1088616A (zh) | 大潜在转化生长因子-β复合物及其有用结构物的生产方法 | |
| US10618949B2 (en) | Method and compositions for producing disulfide-linked trimeric TNF family of cytokines and their use | |
| EA037256B1 (ru) | Химерный белок мочевого трипсинового ингибитора (мти), содержащий домен мти и fc-домен igg1 | |
| CN110172103B (zh) | GLP-1类似物-Fc融合蛋白及其制备方法和用途 | |
| JP2017508446A (ja) | 二機能性融合タンパク質及びその製造方法並びに使用 | |
| US20080292628A1 (en) | Chimeric Protein | |
| US10017555B2 (en) | Long-acting blood sugar decreasing fusion protein | |
| US10968267B2 (en) | Serum albumin-20K growth hormone fusion protein | |
| KR101278690B1 (ko) | 변형된 인간 종양 괴사 인자 수용체-1 폴리펩티드 또는 그의 절편 및 그의 제조방법 | |
| JP2024538452A (ja) | Ｂ細胞活性化因子（ｂａｆｆ）－増殖誘導リガンド（ａｐｒｉｌ）二重阻害剤 | |
| CN116802301A (zh) | Tnfr2与april/baff受体的融合蛋白 | |
| KR101273893B1 (ko) | 변형된 인간 종양 괴사 인자 수용체-1 폴리펩티드 또는 그의 절편 및 그의 제조방법 | |
| JP7375163B2 (ja) | Ｔｇｆ－ベータトラップ | |
| RU2642260C1 (ru) | Полипептид для понижения уровня сахара в крови на основе глюкагоноподобного пептида-1 человека, рекомбинантный штамм-продуцент E. coli и способ получения этого полипептида |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140625 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140716 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20141016 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20141016 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150331 |